CDCA2 upregulation was observed to be associated with shorter overall survival in a subgroup stratified analysis of IDH status (Mut), WHO grade (G3), histological type (astrocytoma and oligodendroglioma), and primary therapy outcome (PD and SD) (S4 Fig). Here, CDCA2 is linked to oligodendroglioma.